Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

New therapeutic agents for myeloproliferative disorders described in recent Exelixis patent

Aug. 31, 2007

In vivo efficacy of BMS-687453, a novel PPARalpha agonist, disclosed by BMS

Aug. 30, 2007

Eculizumab reduces thromboembolism risk in paroxysmal nocturnal hemoglobinuria

Aug. 30, 2007

Indevus seeks FDA approval for male hypogonadism therapy

Aug. 29, 2007

First patient treated in Protalix's phase III trial of prGCD for Gaucher's disease

Aug. 29, 2007

New treatment options for obesity and other metabolic disorders reported in patent literature

Aug. 29, 2007

Recent Wellstat patents describe new treatment options for diabetes

Aug. 29, 2007

Merck discusses SAR data for series of selective MC4 receptor agonists at ACS

Aug. 28, 2007

Bioequivalence achieved with pioglitazone, glimepiride co-therapy and combination tablets

Aug. 28, 2007

New antidiabetic agents divulged in recent patent literature

Aug. 28, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...